ウイルスの核酸とタンパク質を視覚化し、HIV、HTLV、HBV、HCV、ジカウイルス、インフルエンザ感染を監視するためのシングルセルマルチプレックス蛍光イメージング

Executive Industry Relevance

Simultaneous visualization of viral nucleic acids and proteins in single cells addresses a critical gap in antiviral target validation by enabling direct observation of replication dynamics. This capability supports mechanistic de-risking in early discovery by correlating nucleic acid expression with protein production across diverse viral systems. The method enhances predictive confidence in lead identification by providing spatially resolved, quantitative readouts of viral life-cycle stages.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by linking viral nucleic acid transcription to protein synthesis in individual infected cells.
• Operational Value: Reduces mechanistic ambiguity through direct co-localization of DNA, RNA, and protein targets without cross-reactivity between probe sets.
• Scientific Value: Supports functional target validation by visualizing active viral replication stages across HIV, HTLV, HBV, HCV, Zika, and influenza models.

Screening & Assay Development

• Scientific Value: Generates quantitative fluorescence intensity measurements for viral RNA and protein levels, enabling dose-response assessment in compound screening.
• Operational Value: Produces standardized, reproducible single-cell readouts compatible with confocal microscopy for high-content applications.
• Scientific Value: Facilitates assay readiness for antiviral screening by providing simultaneous nucleic acid and protein detection in fixed cells.

Translational & Preclinical Research

• Scientific Value: Tracks viral RNA accumulation over infection courses, such as HBV pre-genomic RNA increase, to inform pharmacokinetic/pharmacodynamic modeling.
• Operational Value: Enables high spatiotemporal resolution imaging of viral processes using 60X oil immersion objectives for detailed mechanistic studies.
• Scientific Value: Serves as a template for multiplexed imaging in broader cellular systems, supporting translational continuity from discovery to preclinical validation.

Pipeline & Workflow Integration

The method integrates into the discovery continuum by providing mechanistic insights post-target identification but prior to lead optimization, particularly for antiviral programs requiring validation of replication inhibitors.

• Discovery Biology: Supports hypothesis testing by visualizing viral nucleic acid export and cytoplasmic protein synthesis in single cells.
• Screening: Delivers quantitative, multiplexed outputs that allow comparison of treatment effects on viral replication and protein expression.
• Analytics: Enables mean integrated fluorescence intensity quantification per cell, facilitating statistical comparison across experimental conditions.
• Translational Research: Connects to preclinical work by modeling viral RNA and protein dynamics relevant to inhibitor efficacy assessment.
• Enterprise Reuse: Establishes a reusable imaging platform applicable to multiple viral pathogens without reformulation of core probe chemistry.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence through direct observation of viral nucleic acid-protein co-expression, reducing false positives in target validation.
• Operational Value: Ensures standardization via branched DNA ISH technology that improves sensitivity over conventional FISH and accommodates immunostaining compatibility.
• Strategic Value: Improves go/no-go decisions by delivering spatially resolved mechanistic data on viral life-cycle progression.
• Portfolio Impact: Enables risk-adjusted prioritization of antiviral candidates based on concurrent nucleic acid and protein suppression metrics.

Implementation Considerations

• Requires expertise in multiplex immunofluorescence and branched DNA in situ hybridization probe handling.
• Depends on hybridization ovens, confocal microscopes, and hydrophobic barrier pens for slide preparation.
• Necessitates standardization of blocking, antibody incubation, and wash protocols across laboratories for reproducible results.
• Involves adaptation considerations when extending to new viral targets or cellular systems due to varying nucleic acid accessibility.
• Includes practical limitations such as the need for RNase treatment controls to confirm RNA-specific signal and overnight drying steps for sample mounting.

Biopharma FAQs